Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: Puma boasts neratinib success in failed Phase II; and three other pipeline updates

This article was originally published in Scrip

Executive Summary

Puma Biotechnology president and CEO Alan Auerbach said the Los Angeles-based company is "very pleased with the results" of a Phase II breast cancer clinical trial in which neratinib failed to improve progression-free survival (PFS) versus Roche/Genentech's Herceptin (trastuzumab) despite a reduction in brain metastases.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel